ImmuPharma has appointed Kymos Group as the bioanalytical partner for its diabetes drug candidate Kapiglucagon, completing its outsourced development team. Kymos will develop and validate methods to measure the drug in biological samples and analyze data from preclinical and planned Phase 1 trials. This follows earlier contracts with Thermo Fisher and Bachem AG for manufacturing and active ingredient production. These partnerships prepare ImmuPharma to file an investigational new drug application in the US, advancing Kapiglucagon towards clinical testing. The drug aims to improve dual-hormone artificial pancreas systems for Type 1 diabetes by overcoming glucagon formulation challenges. The development is funded by a £6.47 million raise and targets a two-year plan, with the autoimmune platform P140 remaining the group's main value driver.
Lockheed Martin received a Buy rating due to its record $230 billion backlog and strong demand for PAC-3 and THAAD missile defense systems. The company’s moderate valuation compared to peers and steady free cash flow yield of about 5.8% support the p...
Arthur Hayes, co-founder of BitMEX, purchased 244,406 UNI tokens for about $1.73 million amid Uniswap's expansion of its protocol-fee system that burns UNI tokens, reducing supply. This mechanism, active since late 2023, links fee collection to token...
Solana attracted $348 million in net real-world asset (RWA) flows over the past 30 days, boosting its total distributed RWA value to about $4.23 billion. This growth outpaced competitors like Ethereum and Stellar, driven by tokenized U.S. Treasury an...
A UK investor named Chris recovered bitcoin worth about $4.5 million after losing access for over 13 years due to the shutdown of the Britcoin/Intersango exchange. He initially bought bitcoin in 2011 for around £1,500 when prices were under $4 per co...
This week saw major AI companies like Anthropic, OpenAI, Meta, and Google release significant updates to their AI models, intensifying competition in the fast-evolving AI market. Nvidia announced a $12.9 billion acquisition of open-source AI platform...
